N. J. WARD ET AL: "Codon optimization of human factor VIII cDNAs leads to high-level expression", BLOOD, vol. 117, no. 3, 20 January 2011 (2011-01-20), pages 798-807, XP055052195, ISSN: 0006-4971, DOI: 10.1182/blood-2010-05-282707 (B1)

William R. Strohl: "Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters", BIODRUGS, Adis International Ltd., NZ, vol. 29, no. 4, 1 August 2015 (2015-08-01) , pages 215-239, NZ ISSN: 1173-8804, DOI: 10.1007/s40259-015-0133-6 (B2)

US-A1- 2009 017 533 (B1)

US-A1- 2009 042 283 (B1)

US-A1- 2010 284 971 (B1)

US-A1- 2013 024 960 (B1)

US-B1- 6 924 365 (B1)

WO-A1-2011/005968 (B1)

WO-A2-2007/149852 (B1)

WO-A2-2013/009627 (B1)

Anonymous: "European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation", Europapress Europapress, 11 March 2009 (2009-03-11), pages 1-3, Retrieved from the Internet: URL:https://www.europapress.es/comunicados /empresas-00908/noticia-comunicado-europea n-commission-approves-refacto-aftm-as-vari ation-to-the-refactor-marketing-authorisat ion-20090311172203.html [retrieved on 2022-06-29] (B2)

Anonymous: "Search Orphan Drug Designations and Approvals", FDA FDA, 2 August 1996 (1996-08-02), pages 1-2, Retrieved from the Internet: URL:https://www.accessdata.fda.gov/scripts /opdlisting/oopd/detailedIndex.cfm?cfgridk ey=094495 [retrieved on 2022-06-29] (B2)

Comparison of codon usage frequency in SEQ ID NO: 1 and SEQ ID: 3 of the Patent and SEQ ID: 5 of D1 (B2)

Comparison of in vivo FVIII activity after expression with codon optimised FVIII (SEQ ID: 1) and non-optimised FVIII (SEQ ID: 3) (B2)

LIND, P. ET AL.: "Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization.", European Journal of Biochemistry, Published by Springer-Verlag on behalf of the Federation of European Biochemical Societies, vol. 232., no. 01., 1 August 1995 (1995-08-01), pages 19-27., ISSN: 0014-2956, DOI: 10.1111/j.1432-1033.1995.tb20776.x (B2)

N. J. Ward et al: "Codon optimization of human factor VIII cDNAs leads to high-level expression", Blood, vol. 117, no. 3, 20 January 2011 (2011-01-20), pages 798-807, ISSN: 00064971, DOI: 10.1182/blood-2010-05-282707 (B2)

SANDBERG H, ET AL.: "STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII", Seminars in Hematology, W.B. Saunders Co., US, vol. 38, no. 02, SUPPL. 04, 1 April 2001 (2001-04-01), pages 04-12, US ISSN: 0037-1963, DOI: 10.1053/shem.2001.25888 (B2)

Sequence alignment of SEQ ID NO: 1 of the opposed patent and SEQ IDNOs: 4-6 of D1 (B2)

Sequence alignment of SEQ ID NOs: 1 and 3 of the opposed patent (B2)

US-B1- 6 316 226 (B2)

VEHAR et al.: Nature, vol. 312, no. 5992, 22 November 1984 (1984-11-22), pages 337-42, (B2)

W. Cao et al: "Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13", Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 105, no. 21, 27 May 2008 (2008-05-27) , pages 7416-7421, ISSN: 0027-8424, DOI: 10.1073/pnas.0801735105 (B2)

WO-A1-03/100053 (B2)

WO-A1-2009/075772 (B2)

WO-A1-2012/170289 (B2)

WO-A2-2011/004361 (B2)

US-A1- 2004 147 436 (B1)